查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1980793

全球非專利癌症治療藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Generic Oncology Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計非專利抗癌藥物市場將從 2025 年的 354.6 億美元成長到 2034 年的 610.3 億美元，2026 年至 2034 年的複合年成長率為 6.22%。

隨著全球對經濟實惠的癌症治療需求持續成長，全球非專利抗癌藥物市場正在迅速擴張。非專利抗癌藥物為品牌抗癌藥物提供了一種價格更親民的替代方案，使更多患者能夠獲得挽救生命的治療。日益加重的全球癌症負擔和不斷上漲的醫療保健成本是推動非專利抗癌藥物普及的主要因素。

多種主要抗癌藥物專利到期，為學名藥​​生產商提供了推出更經濟實惠的治療方案的機會。這些學名藥在保持與品牌藥相同安全性和有效性的同時，顯著降低了治療成本。各國政府和醫療機構都在鼓勵使用學名藥，以提高醫療服務的可近性並降低醫療成本。

隨著越來越多的抗癌藥物專利到期，學名藥上市，全球學名藥市場預計將會成長。製藥公司正增加對大規模生產和監管核准的投資，以擴大其在癌症治療領域的佔有率。隨著人們對價格合理的抗癌療法的需求不斷成長，以及醫療保險覆蓋範圍的擴大，預計該市場將迎來強勁的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球非專利癌症治療市場：依藥物類型分類

  • 市場分析、洞察與預測
  • 化療藥物
  • 標靶治療藥物
  • 免疫療法藥物
  • 荷爾蒙療法藥物
  • 其他藥物類型

第5章 全球非專利癌症治療市場：依適應症分類

  • 市場分析、洞察與預測
  • 攝護腺癌
  • 肺癌
  • 乳癌
  • 結腸癌
  • 白血病
  • 其他跡象

第6章 全球非專利癌症治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 局部的
  • 注射藥物

第7章 全球非專利癌症治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球非專利癌症治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie Inc
    • Apotex Inc
    • AstraZeneca
    • Biocon Ltd
    • Gland Pharma Limited Incyte Corporation
    • Lupin Pharmaceuticals Inc
    • Mylan NV
    • Natco Pharma Ltd
    • Novartis Pharmaceuticals Corporation
    • Pfizer Inc
    • Regeneron Pharmaceuticals Inc
    • Synthon Pharmaceuticals Inc
    • Teva Pharmaceuticals
    • Zydus Lifesciences Limited
簡介目錄
Product Code: VMR112115459

The Generic Oncology Drugs Market size is expected to reach USD 61.03 Billion in 2034 from USD 35.46 Billion (2025) growing at a CAGR of 6.22% during 2026-2034.

The Global Generic Oncology Drugs Market is expanding rapidly as the demand for cost-effective cancer treatments continues to rise worldwide. Generic oncology drugs provide affordable alternatives to branded cancer medications, making life-saving treatments accessible to a larger patient population. The increasing global burden of cancer and rising healthcare costs are major factors driving the adoption of generic oncology therapies.

Patent expirations of several major cancer drugs have opened opportunities for generic drug manufacturers to introduce more affordable treatment options. These medications maintain similar safety and efficacy profiles as branded drugs while significantly reducing treatment expenses. Governments and healthcare providers are encouraging the use of generics to improve accessibility and reduce healthcare expenditure.

In the future, the Global Generic Oncology Drugs Market is expected to grow as more cancer drugs lose patent protection and generic alternatives become available. Pharmaceutical companies are investing in large-scale production and regulatory approvals to expand their presence in the oncology sector. With the increasing demand for affordable cancer therapies and expanding healthcare coverage, the market is projected to experience strong long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

  • Chemotherapy drugs
  • Targeted therapy drugs
  • Immunotherapy drugs
  • Hormonal therapy drugs
  • Other drug types

By Indication

  • Prostate cancer
  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Leukemia
  • Other indications

By Route of Administration

  • Oral
  • Topical
  • Injectable

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

COMPANIES PROFILED

  • AbbVie Inc, Apotex Inc, AstraZeneca, Biocon Ltd, Gland Pharma Limited Incyte Corporation, Lupin Pharmaceuticals Inc, Mylan NV, Natco Pharma Ltd, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron Pharmaceuticals Inc, Synthon Pharmaceuticals Inc, Teva Pharmaceuticals, Zydus Lifesciences Limited
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Type
  • 4.2. Chemotherapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Targeted therapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Immunotherapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Hormonal therapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Other drug types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Indication
  • 5.2. Prostate cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Lung cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Breast cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Colorectal cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Other indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Drug Type
    • 8.2.2 By Indication
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Drug Type
    • 8.3.2 By Indication
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Drug Type
    • 8.4.2 By Indication
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Drug Type
    • 8.5.2 By Indication
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Drug Type
    • 8.6.2 By Indication
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GENERIC ONCOLOGY DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AbbVie Inc
    • 10.2.2 Apotex Inc
    • 10.2.3 AstraZeneca
    • 10.2.4 Biocon Ltd
    • 10.2.5 Gland Pharma Limited Incyte Corporation
    • 10.2.6 Lupin Pharmaceuticals Inc
    • 10.2.7 Mylan N.V
    • 10.2.8 Natco Pharma Ltd
    • 10.2.9 Novartis Pharmaceuticals Corporation
    • 10.2.10 Pfizer Inc
    • 10.2.11 Regeneron Pharmaceuticals Inc
    • 10.2.12 Synthon Pharmaceuticals Inc
    • 10.2.13 Teva Pharmaceuticals
    • 10.2.14 Zydus Lifesciences Limited